The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0 mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0 mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years). The hazard ratio for liraglutide 3.0 mg compared to comparators was 0.42 (95% confidence interval, 0.17-1.08). In this analysis, liraglutide 3.0 mg treatment was not associated with excess cardiovascular risk. However, the wide confidence intervals and retrospective adjudication of events in two of the trials are limitations of the analysis.
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| INTRODUCTION
Obesity is a chronic disease, and a risk factor for the development of type 2 diabetes mellitus (T2DM) and cardiovascular disease; obesity is also associated with an increased risk of cardiovascular mortality. 1 While weight loss can lead to improvements in cardiovascular risk factors (waist circumference, blood pressure, lipid profile, cardiovascular biomarkers and glucose homeostasis), its association with improved cardiovascular outcomes is less clear. 2, 3 Several anti-obesity medications have been linked to increased blood pressure, heart rate and cardiovascular risk, leading to marketing authorization withdrawal. 4 Regulatory authorities now require all new obesity and T2DM medications to demonstrate no excess cardiovascular health risks. [5] [6] [7] [8] 
| Cardiovascular event adjudication
Cardiovascular events were adjudicated prospectively by a blinded event adjudication committee for 3 of the SCALE trials (Table S1 ).
For the phase 2 trial and the SCALE Maintenance trial, events were identified by searching the trial database for specific Medical Dictionary for Regulatory Activities (MedDRA) terms and serious adverse events recorded by trial investigators, as described in Appendix S1.
Events found in each search were then adjudicated retrospectively and independently by blinded medical experts.
| Statistical analysis
The Table S2 . Mean and categorical weight loss achieved in each of the trials is shown in Table S3 .
The incidence of cardiovascular events in each trial and analysis is shown in Table 1 . Figure 1A Table S4 .
Mean pooled changes in blood pressure and pulse are shown in Table S5 for trials of up to 1-year duration. Liraglutide 3.0 mg was associated with significantly reduced mean systolic and diastolic blood pressure compared to placebo in each of the trials, with estimated treatment differences of −2.9 (95% CI, −3.5 to −2.3) and −0. Abbreviations: CI, confidence interval; HR, hazard ratio; N, total number of participants in each analysis; T2DM, type 2 diabetes mellitus. The number of participants with adjudicated cardiovascular events and the incidence rate are shown by treatment group. Person-years were counted until the time of first event or censoring. Cardiovascular events were defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Exposure time included 30 days after the last treatment date or last visit, as applicable. The endpoint in all analyses was time to first event; 2 participants had an additional event each, see Table S4 .
a Primary analysis.
b All comparators group included treatment with placebo (n = 1941) and orlistat (n = 95). No events were reported in the orlistat treatment group, from the phase 2 trial.
c Excluding participants in the liraglutide group who were re-randomized to placebo in the re-randomized period of the 56-week trial.
d For participants randomized to placebo, data are included only up to 1 year, after which participants switched to treatment with liraglutide. medication remains unproven. 15 In the Sibutramine Cardiovascular OUTcomes (SCOUT) trial, while more events of nonfatal myocardial infarction occurred in a high-risk population in the sibutramine group compared with the placebo group, greater weight loss was associated with reduced cardiovascular mortality in both treatment groups. (Table S4) ; however, the composite analysis includes only the first event for each participant
The underlying mechanism of the increase in resting pulse with liraglutide remains to be determined. Preliminary data indicate the presence of GLP-1 receptors on the sino-atrial node in nonhuman primates and humans, suggesting a direct chronotropic effect of liraglutide. 17 Limitations of this analysis include the wide confidence intervals and the retrospective adjudication of events in 2 of the trials. Moreover, there was no consistent follow-up for participants who discontinued prematurely (approximately 50% of randomized participants after 3 years) and were censored in the analysis; associations between the risks of censoring and cardiovascular events cannot be ruled out. Strengths of this analysis include the large number of participants and the fact that events were prospectively adjudicated in most of the trials.
In summary, liraglutide 3.0 mg treatment was not associated with excess cardiovascular risk in this analysis of data from the phase 2 and 3a SCALE clinical trials.
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